Unii-4U07F515lg

Unii-4U07F515lg

Unii-4U07F515lg

Min.Order / FOB Price:Get Latest Price

1 Gram

Negotiable

  • Min.Order :1 Gram
  • Purity: 99% purity
  • Payment Terms : T/T,Other

Keywords

Unii-4U07F515lg 496775-62-3 99% purity

Quick Details

  • Appearance:powder
  • Application:intermediate
  • PackAge:accroding to the need
  • ProductionCapacity:100|Kilogram|Day
  • Storage:Sealed in dry,Room Temperature
  • Transportation:air,sea and courier

Superiority:

Product Name:    Unii-4U07F515lg
Synonyms:    Eltrombopag olamine;Sb 497115gr;Unii-4U07F515lg;3'-[(2Z)-2-[1-(3,4-DiMethylphenyl)-1,5-dihydro-3-Methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid coMpd. with 2-aMinoethanol(1:2);EltroMbopag diethanolaMine salt;EltroMbopag OlaMine API;EltroMbopag IMpurity;Eltrombopag Diolamine                         
CAS:    496775-62-3          
MF:    C27H29N5O5          
MW:    503.56           
EINECS:    629-876-8                    
Mol File:    496775-62-3.mol                

Details:

Unii-4U07F515lg Chemical Properties
storage temp.     Keep in dark place,Inert atmosphere,2-8°C
Safety Information
MSDS Information
Unii-4U07F515lg Usage And Synthesis
Uses    Treatment of chemotherapy-induced thrombocytopenia and treatment of immune thrombocytopenic purpura.
Clinical Use    Eltrombopag olamine, a thrombopoietin receptor (TpoR) agonist, was approved in late 2008 for the once-daily, oral short-term and long-term treatment of adult patients with previously treated chronic idiopathic thrombocytopenic purpura (ITP). It is the first small-molecule TpoR agonist and was launched in the U.S. for this indication in 2009 by GlaxoSmithKline (GSK). Because eltrombopag is a small molecule, the drug is administered orally and has a reduced potential for causing an immune system reaction versus alternative protein-based therapies. In 2010, eltrombopag was approved in Europe for the long-term treatment of adult patients with previously treated chronic ITP.
Chemical Synthesis    The synthesis began with the nitration of 2-bromophenol (39) with sodium nitrate and sulfuric acid in water at 10°C to give 2-bromo-6-nitrophenol (40) in 25% yield, which was methylated using methyl iodide and potassium carbonate in refluxing acetone providing 2-bromo- 6-nitroanisole (41) in 76% yield (the Scheme).40 Suzuki coupling of compound 41 with 3-carboxyphenyl boronic acid with Pd(PPh3)4 and 2 M sodium carbonate in refluxing dioxane gave 20-methoxy- 30-nitrobiphenyl-3-carboxylic acid (42) in 47% yield as a tan powder. Demethylation using 48% HBr (aq) in refluxing acetic acid resulted in a 79% yield of 20-hydroxy-30-nitrobiphenyl-3-carboxylic acid (43). The nitro group of compound 43 was reduced via catalytic hydrogenation at 50 psi at room temperature over Pd/C in mixed ethanol/3 M aq NaOH solution to give 30-amino-20-hydroxybiphenyl- 3-carboxylic acid (44) in quantitative yield. The intermediate 1-(3,4-dimethylphenyl)-3-methyl-2,5-dihydro-1Hpyrazol- 5-one (47) was prepared by condensing of 3,4-dimethylphenyl- hydrazine 45 with ethyl acetoacetate 46 with sodium acetate in refluxing acetic acid in 76% yield. Treatment of (44) with sodium nitrite in 1 M HCl at 5°C, followed by condensation with 1-(3,4-dimethylphenyl)-3-methyl-2,5-dihydro-1H-pyrazol-5-one (47) at a constant pH of 7–8 via the addition of sodium bicarbonate and ethanol afforded eltrombopag in 32% yield. Finally, eltrombopag was treated with hydroxyl ethylamine to give eltrombopag olamine (VIII).
 

Related Searches

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View